CA3056517A1 - Molecules de liaison se liant specifiquement a tau - Google Patents
Molecules de liaison se liant specifiquement a tau Download PDFInfo
- Publication number
- CA3056517A1 CA3056517A1 CA3056517A CA3056517A CA3056517A1 CA 3056517 A1 CA3056517 A1 CA 3056517A1 CA 3056517 A CA3056517 A CA 3056517A CA 3056517 A CA3056517 A CA 3056517A CA 3056517 A1 CA3056517 A1 CA 3056517A1
- Authority
- CA
- Canada
- Prior art keywords
- tau
- binding
- binding molecule
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne des molécules de liaison et des des fragments de liaison à l'antigène qui se lient de manière spécifique à la protéine tau associée aux microtubules. L'invention concerne également des procédés de diagnostic, prophylactiques et thérapeutiques utilisant les molécules de liaison ou les fragments de liaison à l'antigène.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17163425 | 2017-03-28 | ||
EP17163425.6 | 2017-03-28 | ||
PCT/EP2018/057770 WO2018178077A1 (fr) | 2017-03-28 | 2018-03-27 | Molécules de liaison se liant spécifiquement à tau |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3056517A1 true CA3056517A1 (fr) | 2018-10-04 |
Family
ID=58448491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3056517A Pending CA3056517A1 (fr) | 2017-03-28 | 2018-03-27 | Molecules de liaison se liant specifiquement a tau |
Country Status (10)
Country | Link |
---|---|
US (1) | US11028157B2 (fr) |
EP (1) | EP3601335A1 (fr) |
JP (1) | JP7109467B2 (fr) |
KR (1) | KR20190133191A (fr) |
CN (1) | CN110418804A (fr) |
AU (1) | AU2018241857A1 (fr) |
CA (1) | CA3056517A1 (fr) |
EA (1) | EA201992281A1 (fr) |
SG (1) | SG11201907927SA (fr) |
WO (1) | WO2018178077A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20152004A1 (es) | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | Inmunoterapia tau |
KR102506091B1 (ko) | 2016-05-02 | 2023-03-07 | 프로테나 바이오사이언시즈 리미티드 | 타우 면역요법 |
CU24537B1 (es) | 2016-05-02 | 2021-07-02 | Prothena Biosciences Ltd | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6 |
CN110520440A (zh) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | 抗τ抗体及其使用方法 |
AU2018263935A1 (en) | 2017-05-02 | 2019-12-19 | Prothena Biosciences Limited | Antibodies recognizing tau |
JP2022524588A (ja) | 2019-03-03 | 2022-05-09 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
GB201909393D0 (en) | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
WO2023092004A1 (fr) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions et méthodes pour le traitement de troubles liés à tau |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE447617T1 (de) | 1999-04-15 | 2009-11-15 | Crucell Holland Bv | Verwendung von rekombinanten proteinen in menschlichen zellen |
SI2627672T1 (sl) * | 2010-10-11 | 2018-10-30 | Biogen International Neuroscience Gmbh | Človeška protitelesa anti-tau |
US8697076B2 (en) * | 2011-04-27 | 2014-04-15 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
AU2012311234B2 (en) * | 2011-09-19 | 2017-09-28 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease |
EP3486256A3 (fr) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention B.V. | Anticorps et fragments de liaison à l'antigène qui se lient spécifiquement à la protéine tau associée aux microtubules |
ZA201608812B (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
ES2848376T3 (es) * | 2014-11-19 | 2021-08-09 | Axon Neuroscience Se | Anticuerpos de tau humanizados en la enfermedad de Alzheimer |
-
2018
- 2018-03-27 EP EP18715587.4A patent/EP3601335A1/fr not_active Withdrawn
- 2018-03-27 CN CN201880015336.1A patent/CN110418804A/zh active Pending
- 2018-03-27 WO PCT/EP2018/057770 patent/WO2018178077A1/fr unknown
- 2018-03-27 EA EA201992281A patent/EA201992281A1/ru unknown
- 2018-03-27 CA CA3056517A patent/CA3056517A1/fr active Pending
- 2018-03-27 AU AU2018241857A patent/AU2018241857A1/en not_active Abandoned
- 2018-03-27 JP JP2019552923A patent/JP7109467B2/ja active Active
- 2018-03-27 US US16/497,916 patent/US11028157B2/en active Active
- 2018-03-27 SG SG11201907927S patent/SG11201907927SA/en unknown
- 2018-03-27 KR KR1020197030544A patent/KR20190133191A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018178077A1 (fr) | 2018-10-04 |
JP2020511976A (ja) | 2020-04-23 |
US20210122810A1 (en) | 2021-04-29 |
EA201992281A1 (ru) | 2020-02-13 |
EP3601335A1 (fr) | 2020-02-05 |
SG11201907927SA (en) | 2019-10-30 |
CN110418804A (zh) | 2019-11-05 |
JP7109467B2 (ja) | 2022-07-29 |
AU2018241857A1 (en) | 2019-09-19 |
KR20190133191A (ko) | 2019-12-02 |
US11028157B2 (en) | 2021-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11028157B2 (en) | Binding molecules that specifically bind to tau | |
EP3160999B1 (fr) | Anticorps et fragments de liaison à l'antigène qui se lient spécifiquement à la protéine tau associée aux microtubules | |
US20200369754A1 (en) | Binding molecules that specifically bind to tau | |
EP3135689B1 (fr) | Anticorps phosphospécifiques reconnaissant tau | |
US11274147B2 (en) | Binding molecules that specifically bind to tau | |
JP2022502369A (ja) | α−シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法 |